Sionna Therapeutics (NASDAQ:SION) Issues Earnings Results

Sionna Therapeutics (NASDAQ:SION) issued its earnings results on Thursday. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.02), FiscalAI reports.

Sionna Therapeutics Price Performance

SION traded up $0.78 during trading on Friday, reaching $50.39. 317,689 shares of the stock were exchanged, compared to its average volume of 400,873. The company has a market capitalization of $2.28 billion, a price-to-earnings ratio of -26.10 and a beta of 1.33. The business’s 50 day moving average price is $42.18 and its two-hundred day moving average price is $40.33. Sionna Therapeutics has a 1 year low of $17.09 and a 1 year high of $54.97.

Insider Buying and Selling

In other news, Director Peter A. Thompson sold 85,918 shares of the company’s stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $44.86, for a total value of $3,854,281.48. Following the sale, the director directly owned 2,469,959 shares in the company, valued at $110,802,360.74. This represents a 3.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 85,918 shares of the stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $44.86, for a total value of $3,854,281.48. Following the sale, the director directly owned 2,469,959 shares in the company, valued at approximately $110,802,360.74. The trade was a 3.36% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 773,004 shares of company stock worth $35,327,383. 5.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in SION. Deutsche Bank AG purchased a new stake in shares of Sionna Therapeutics during the 2nd quarter valued at about $2,347,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in Sionna Therapeutics during the 2nd quarter valued at approximately $44,000. Bank of New York Mellon Corp purchased a new stake in Sionna Therapeutics during the 2nd quarter worth approximately $1,829,000. State of Wyoming purchased a new stake in Sionna Therapeutics during the 2nd quarter worth approximately $35,000. Finally, Walleye Capital LLC acquired a new position in shares of Sionna Therapeutics in the 2nd quarter valued at approximately $4,282,000.

Analyst Ratings Changes

A number of analysts have issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Sionna Therapeutics in a research note on Wednesday. Citizens Jmp reissued a “market outperform” rating and issued a $63.00 price objective on shares of Sionna Therapeutics in a research note on Tuesday, May 26th. Guggenheim restated a “buy” rating and issued a $60.00 price objective on shares of Sionna Therapeutics in a report on Friday. Stifel Nicolaus upped their price objective on Sionna Therapeutics from $44.00 to $55.00 and gave the stock a “buy” rating in a research report on Monday, May 18th. Finally, Wall Street Zen cut Sionna Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Three investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $55.00.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.